Hosted on MSN2d
Olpasiran Leads to Significant Reduction in Oxidized Phospholipids
Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a]) production, leads to a significant and sustained ...
Clinical trial finds RNA inhibitor effectively reduces 'bad cholesterol' in patients with cardiovascular disease
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...
emjreviews.com4d
OCEAN(a)-DOSE Trial: New Data on Lipoprotein(a) and Oxidized Phospholipids
Olpasiran reduces oxidized phospholipids but not inflammation in cardiovascular disease—what does this mean for clinical care ...
News Medical on MSN11d
Olpasiran significantly lowers "bad cholesterol" linked to cardiovascular risk
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...
Armed robbery in Revesby11d
RNA Inhibitor May Cut High-Risk Cholesterol in Patients
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according ...
technologynetworks6d
RNA Inhibitor Reduces “Bad Cholesterol” in Patients With Cardiovascular Disease
A phase 2 trial shows that olpasiran, an RNA-based therapy, reduces lipoprotein(a) [Lp(a)] levels by more than 95% in ...